Dr. Debra Louise Bowen, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 254 Methodist Dr, Lake Junaluska, NC 28745 Phone: 828-456-9039 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
A root canal ranks high on most people's list of dreaded dental procedures. Although the lengthy and sometimes painful surgery relieves the agony of an infection, a root canal results in a dead tooth with no living soft tissue, or dental pulp, inside.
A team of researchers from the USA, Germany and Norway recently found that the main barrier to vaccination is not vaccine hesitancy but a supply shortage and unequal distribution of the vaccines themselves.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 7 days ago